文献速递血栓与止血

基于聚类分析识别血栓性原发性抗磷脂综合征的表型:迈向个体化医疗的一步

Identification of phenotypes in thrombotic primary antiphospholipid syndrome using cluster analysis: a step toward personalized medicine.
PubMed 文献 · J Thromb Haemost · 2025-06-13

这项多中心回顾性队列研究纳入2018-2023年巴西、以色列和墨西哥的663例血栓性原发性抗磷脂综合征患者,采用层次聚类分析基于人口学、血栓特征、合并症和实验室数据识别出3种不同表型。三种表型分别以心血管危险因素为主、以高凝状态为主和以免疫学异常为主。研究认为这些发现为制定个体化管理策略提供了基础。

要点

  • 聚类分析识别出3种血栓性原发性抗磷脂综合征表型。
  • 第1类以年长、心血管危险因素高和动脉血栓为主。
  • 第2类以年轻、静脉血栓栓塞高复发和抗心磷脂抗体高 prevalencia 为主。

核心结论

  • 本研究识别出3种不同的血栓性原发性抗磷脂综合征表型,分别以心血管危险因素、高凝状态或免疫学异常为主。
  • 研究认为这些发现为制定个体化管理策略以改善患者结局提供了基础。

研究设计与样本

  • 多中心回顾性队列研究,纳入2018-2023年在巴西、以色列和墨西哥随访的663例血栓性原发性抗磷脂综合征患者。
  • 采用层次聚类分析,基于人口学、血栓特征、合并症和实验室数据对患者进行分类。

主要发现

  • 第1类(n=348)为年长患者(中位年龄43岁),心血管危险因素(高血压、糖尿病和血脂异常)高,以动脉血栓为主(53%,P < .001)。
  • 第2类(n=119)为较年轻患者(中位年龄35岁),静脉血栓栓塞复发率高(71%,P < .001),静脉血栓栓塞占80%(P < .001),抗心磷脂抗体阳性率较高(29%,P < .001)。
  • 第3类(n=196)为最年轻患者(中位年龄29岁),以三抗磷脂抗体阳性为主(98.5%,P < .001),伴补体消耗(C3:17%,P = .003)、血小板减少(12%,P = .05)和静脉血栓形成(73%,P < .001)。

临床怎么用

  • 原文结论认为这些发现为制定个体化管理策略以改善患者结局提供了基础,未据此给出具体推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Thrombotic risk in primary antiphospholipid syndrome (APS) is a result of complex, yet undefined, interactions among multiple factors. While long-term anticoagulation reduces thrombotic complications, its efficacy varies, with thrombosis recurrence rates ranging from 5% to 20% within 2 years. Emerging therapies may benefit specific APS subgroups, although identifying and stratifying these groups remains a significant challenge. OBJECTIVES: To identify specific phenotypic subgroups of thrombotic primary APS based on clinical and laboratory characteristics to provide insight for both personalized diagnostic and therapeutic strategies. METHODS: Multicenter retrospective cohort study including 663 patients with thrombotic primary APS who were followed in Brazil, Israel, and Mexico (2018-2023). Hierarchical cluster analysis categorized patients based on demographics, thrombotic characteristics, comorbidities, and laboratory data. RESULTS: Cluster analysis identified 3 distinct phenotypes. Cluster 1 (n = 348) included older patients (median age 43 years) with high cardiovascular risk factors (hypertension, diabetes, and dyslipidemia) and predominantly arterial thrombosis (53%, P < .001). Cluster 2 (n = 119) included younger patients (median age 35 years) with high recurrence rates (71%, P < .001) of venous thromboembolism (80%, P < .001) and higher anticardiolipin prevalence (29%, P < .001). Cluster 3 (n = 196) featured the youngest patients (median age 29 years), predominantly triple antiphospholipid antibody positive (98.5%, P < .001), with complement consumption (C3: 17%, P = .003), thrombocytopenia (12%, P = .05), and venous thrombosis (73%, P < .001). CONCLUSION: This study identified 3 distinct phenotypes of thrombotic primary APS, each characterized by the predominance of cardiovascular risk factors, hypercoagulability, or immunologic derangements. The findings provide a basis for developing personalized management strategies to improve patient outcomes.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Santos GM, David P, Hen O, et al. Identification of phenotypes in thrombotic primary antiphospholipid syndrome using cluster analysis: a step toward personalized medicine. J Thromb Haemost. 2025. PMID: 40518049. doi:10.1016/j.jtha.2025.06.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。